Dr Joshua Savage

Dr Joshua Savage

Institute of Cancer and Genomic Sciences
Trial Management Team Leader

Contact details

Telephone
+44 (0)121 415 8421
Fax
+44 (0)121 414 3529
Email
j.savage.1@bham.ac.uk
Address
Cancer Research UK Clinical Trials Unit (CRCTU)
Institute of Cancer and Genomic Sciences
University of Birmingham
Edgbaston
Birmingham
B15 2TT

Dr Joshua Savage is the Early Drug Development Trial Management Team Leader at the Cancer Research UK Clinical Trials Unit (CRCTU), Institute of Cancer and Genomic Sciences at the University of Birmingham.

Qualifications

  • PhD Pharmacology, University of Bristol, 2012
  • BSc (Hons) Biochemistry, University of Bristol, 2008

Biography

Joshua Savage graduated with a BSc. (Hons) in Biochemistry from the University of Bristol in 2008. Following this he was awarded a Biotechnology and Biological Sciences Research Council studentship to study for a PhD at the University of Bristol, investigating the functional role of protein kinases in thrombosis in heart disease in the laboratory of Professor Alastair Poole in 2008.

Joshua joined the Adult Late Phase Team (B Team) of the Cancer Research UK Clinical Trials Unit at the University of Birmingham in 2013, coordinating academically sponsored late phase trials in skin (UKMCC-01, SPOT) and head & neck cancer (CompARE). In 2015 he was promoted to Senior Trial Coordinator within the B team, then later that year moved to the Children’s Cancer Trials Team.  Joshua worked primarily on international studies in the late phase solid tumour portfolio, focussing on Ewing’s sarcoma (EE2012, rEECur), rhabdomyosarcoma (RMS2005, FaR-RMS), and neuroblastoma (IMAT, HRNBL1), whilst also supporting the myeloid leukaemia study, MyeChild-01.

In 2018 Joshua was appointed as the EDD Trial Management Team Leader, and leads the trials team for a number of early phase cancer trials including the National Lung Matrix Trial, Tessa Jowell BRAIN MATRIX and ANICCA-Class II.

Teaching

Publications

Recent publications

Article

Middleton, G, Brock, K, Savage, J, Mant, R, Summers, Y, Connibear, J, Shah, R, Ottensmeier, C, Shaw, P, Lee, SM, Popat, S, Barrie, C, Barone, G & Billingham, L 2020, 'Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial', The Lancet Respiratory Medicine. https://doi.org/10.1016/S2213-2600(20)30033-3

Kong, A, Good, JS, Kirkham, A, Savage, J, Mant, R, Llewellyn, L, Parish, J, Spruce, R, Forster, M, Schipani, S, Harrington, K, Sacco, JJ, Murray, P, Middleton, G, Yap, C & Mehanna, H 2020, 'A phase I trial of WEE1 inhibition with chemotherapy and radiotherapy as adjuvant treatment, and a window of opportunity trial with cisplatin in patients with head and neck cancer: the WISTERIA trial protocol', BMJ open, vol. 10, no. 3, e033009. https://doi.org/10.1136/bmjopen-2019-033009